Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722399 | 0.92 | PPARG (0.49) | PPARGHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6715769 | 0.85 | NPC1 (0.48) | PPARGHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6714898 | 0.78 | PPARG (0.46) | PPARGHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6718840 | 0.78 | NPC1 (0.52) | PPARGHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6718821 | 0.78 | NPC1 (0.52) | PPARGHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6713267 | 0.77 | PPARG (0.52) | PPARGHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6713340 | 0.77 | NPC1 (0.53) | PPARGHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6714956 | 0.77 | PPARG (0.56) | PPARGHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6722548 | 0.76 | PPARG (0.52) | PPARGHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6713446 | 0.75 | PPARG (0.52) | PPARGHPGDSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | PPARG 23/4885HPGD 1069/4885SMN1; SMN2 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.